| Identification | Back Directory | [Name]
Zansecimab | [CAS]
2415205-37-5 | [Synonyms]
Zansecimab
Zansecimab (anti-ANGPT2)
Research Grade Zansecimab (DHA42304) |
| Hazard Information | Back Directory | [Uses]
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation[1][2][3]. | [References]
[1] Yen CC, et al. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf. 2022 Feb;21(2):157-166. DOI:10.1080/14740338.2022.1995353
[2] Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5;910:174500. DOI:10.1016/j.ejphar.2021.174500 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|